New Market Research Report: Hong Kong Pharmaceuticals & Healthcare Report Q4 2013

From: Fast Market Research, Inc.
Published: Thu Sep 12 2013

BMI View: The attractiveness of Hong Kong's pharmaceutical market is dependent on its proximity to China as pharmaceutical firms are able to leverage on Hong Kong's relatively safe operating environment to expand into China. However, as China continues to advance in biotechnology and pharmaceutical, it will become a threat over the long term. Equally relevant is its domestic demographic, where is ageing and affluent population will continue to sustain demands for pharmaceuticals and healthcare services. Similar to Singapore, Hong Kong's long-term growth potential is nevertheless limited by its small market size.

Full Report Details at

Headline Expenditure Projections

* Pharmaceuticals: HKD10.31bn (US$1.33bn) in 2012 to HKD10.94bn (US$1.41bn) in 2013; +6.1% in local currency terms and +5.9% in US dollar terms. Forecast broadly in line with Q312.
* Healthcare: HKD112.43bn (US$14.49bn) in 2012 to HKD120.53bn (US$15.51bn) in 2013; +7.2% in local currency terms and +7.0% in US dollar terms. Forecast broadly in line with Q312.

Risk/Reward Ratings

Hong Kong's Pharmaceutical Risk/Reward Rating (RRR) score for Q413 is 59.0 out of the maximum 100 in our newly improved RRR system. The country scored above average for most of indicators and subindicators including per capita pharmaceutical expenditure, sector value growth and pensionable population. Consequently with this high score, Hong Kong is ranked eighth, behind Malaysia but in front of India, among the 19 key Asia Pacific markets.

Key Trends And Developments

* In June, a licensed wholesaler of proprietary Chinese medicine (pCm), Hong Kong-based Beijing Tong Ren Tang Hong Kong Medicine Management Limited, has been directed to withdraw a batch of pCm from consumers. The order was issued by the Hong Kong Department of Health on June 4 2013. The move follows the discovery of nearly five times the level of mercury allowed by the local government laboratory in a sample
* In the same month, MMRGlobal reported that it is to receive Hong Kong Patent No. 1052295B. The patent, entitled: "Method and Composition for Altering a B-Cell Mediated Pathology" protects certain methods of manufacturing compositions for B-cell vaccines used in the fight against lymphoma and potentially other forms of cancer.
* In May 2013, DKSH Business Unit Healthcare and UK-based drugmaker GlaxoSmithKline (GSK) have signed a deal for the commercialisation of the latter's antibiotics in Hong Kong. Under the deal, DKSH will provide contract sales services in private clinics and trade channel for GSK's antibiotic product line.

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at or call us at 1.800.844.8156.

You may also be interested in these related reports:

- Nigeria Pharmaceuticals & Healthcare Report Q4 2013
- Kenya Pharmaceuticals & Healthcare Report Q4 2013
- Latvia Pharmaceuticals & Healthcare Report Q4 2013
- Pakistan Pharmaceuticals & Healthcare Report Q4 2013
- Mexico Pharmaceuticals & Healthcare Report Q4 2013
Company: Fast Market Research, Inc.
Contact Name: Bill Thompson
Contact Email:
Contact Phone: 1-413-485-7001

Visit website »